Westfield Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Westfield Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-758,356	Closed	-$20.4M	–	256
2022 Q1	$20.4M	Buy	758,356 +72,807	+11%	+$2.45M	0.13%	167
2021 Q4	$32.7M	Sell	685,549 -250,942	-27%	-$11.2M	0.19%	146
2021 Q3	$62.2M	Buy	936,491 +28,731	+3%	+$2.05M	0.38%	98
2021 Q2	$70.8M	Buy	907,760 +494,755	+120%	+$36.6M	0.42%	89
2021 Q1	$39.1M	Buy	413,005 +22,038	+6%	+$2.62M	0.24%	132
2020 Q4	$47.6M	Buy	390,967 +88,348	+29%	+$9.68M	0.28%	122
2020 Q3	$26.4M	Buy	302,619 +46,541	+18%	+$3.24M	0.17%	158
2020 Q2	$16.5M	Buy	256,078 +79,657	+45%	+$4.6M	0.11%	182
2020 Q1	$7.88M	Buy	+176,421	New	+$9.37M	0.07%	183
2019 Q3	–	Sell	-5,500	Closed	-$224K	–	260
2019 Q2	$224K	Buy	+5,500	New	+$196K	﹤0.01%	242

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Westfield Capital Management's TPTX Position: Q2 2022 in Review

Westfield Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 758,356 shares — an estimated $20.4M sold.

Westfield Capital Management first reported a position in TPTX in Q2 2019 and held it in 10 quarters. The position peaked at $70.8M in Q2 2021. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Westfield Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Westfield Capital Management sold 758,356 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $20.4M.
Westfield Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Westfield Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $70.8M in Q2 2021.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Westfield Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.